Welcome to our dedicated page for Monopar Therapeutics SEC filings (Ticker: MNPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Monopar Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Monopar Therapeutics's regulatory disclosures and financial reporting.
Monopar Therapeutics (MNPR) director Kim R. Tsuchimoto reported an amended set of transactions on August 26, 2026, correcting a prior Form 4. The director exercised stock options for 2,055 shares at an exercise price of $30.00 and 2,035 shares at $14.00, receiving an equal number of common shares. On the same date, a total of 4,090 common shares were sold in multiple trades at weighted average prices between $108.83 and $113.84 per share, with underlying trade ranges from $108.07 to $114.34. All option exercises and sales were effected pursuant to a Rule 10b5-1 Plan executed on May 27, 2026. Following these transactions, 11,486 shares are reported as held indirectly by the Kim R. Tsuchimoto Trust dated October 6, 2015.
Monopar Therapeutics (MNPR) director Raymond Anderson amended a prior insider report to include previously omitted option exercises and to reflect Monopar’s 5-for-1 reverse stock split effective August 12, 2024. On August 25, 2026, he exercised options for 3,142 shares of common stock at a $30.00 exercise price and sold 3,142 shares in three open-market transactions at weighted average prices of $110.04, $111.07, and $113.05. All transactions were effected under a Rule 10b5-1 trading plan executed on May 26, 2026.
Monopar Therapeutics (MNPR) reported that Acting Chief Medical Officer Patrice Rioux exercised 1,380 Stock Options for Common Stock on 2026-08-26 at an exercise price of $0.005 per share, converting them into 1,380 Common Shares. On the same date, 1 Common Share was sold at $111.26 per share. The option exercise exhausted this particular option grant, leaving 0 derivative shares reported as remaining from it. These transactions were effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.
Monopar Therapeutics (MNPR) director Tsuchimoto Kim R reported multiple open-market sales of common stock. On August 26, 2026, the reporting person sold a total of 4,090 shares of Monopar common stock in six transactions, each reported at a weighted average price between $108.83 and $113.84 per share. The trades were effected pursuant to a Rule 10b5-1 Plan executed on May 27, 2026, and each sale was executed through multiple trades within disclosed price ranges.
Monopar Therapeutics (MNPR) director Raymond Anderson reported selling a total of 3,142 shares of common stock on August 25, 2026 in three open-market transactions under a Rule 10b5-1 trading plan executed on May 26, 2026. The reported per-share prices are weighted averages for shares sold across disclosed price ranges.
Monopar Therapeutics (MNPR) insider Patrice Rioux, Acting Chief Medical Officer, filed a Rule 144 notice to sell 1 share of Monopar common stock. The planned sale, through Morgan Stanley Smith Barney LLC, is tied to an exercise of stock options for cash on or about August 26, 2026, with Form 144 indicating 6,712,172 shares outstanding and an aggregate market value reference of $110.82 for the shares to be sold.
Monopar Therapeutics (MNPR) director Kim Tsuchimoto filed a Rule 144 notice to sell up to 8,180 shares of Monopar common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an approximate sale date of 08/26/2026 and over the next three months via exercise of stock options for cash.
The filing lists an aggregate market value for the planned sale of $906,507.60. Monopar common shares outstanding are reported as 6,712,172, providing context for the relative size of this planned insider sale.
Monopar Therapeutics (MNPR) has a notice from director Raymond William Anderson to sell shares of its common stock under Rule 144. The notice covers 6,284 shares of common stock, to be received and sold upon the exercise of stock options over a three‑month period, with trades listed for NASDAQ and handled through Morgan Stanley Smith Barney LLC. The securities will be paid for in cash, and the stated date associated with the proposed sale is 08/25/2026.
Monopar Therapeutics received an updated Schedule 13G/A from Saturn V Capital Management LP and Xiaoying Tian reporting their beneficial ownership of the company’s common stock. The reporting persons state that clients advised by Saturn V collectively hold 313,384 shares of Monopar common stock.
This position represents 4.68% of the common stock, based on 6,699,062 shares outstanding as of April 30, 2026, as disclosed in Monopar’s Form 10-Q. Saturn V and Tian report 0 shares with sole voting or dispositive power and 313,384 shares with shared voting and shared dispositive power.
The shares are held across pooled investment vehicles and managed accounts (the “Clients”), none of which individually owns 5% or more of Monopar’s outstanding shares. Saturn V and Tian each disclaim beneficial ownership of the shares held by the Clients and indicate that their aggregate ownership is 5 percent or less of the class.
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports beneficial ownership of Monopar Therapeutics Inc. common stock. The group reports 324,195 shares of common stock, including 115,000 shares issuable upon exercise of warrants, with no sole voting or dispositive power and full holdings under shared voting and shared dispositive power.
Based on 6,699,062 shares outstanding as of April 30, 2026, the reporting persons state their beneficial ownership represents 4.76% of Monopar’s common stock, indicating ownership of 5 percent or less of the class. The securities are held through Adage Capital Partners, L.P., for which Adage Capital Management, L.P. acts as investment manager.